Viracta Therapeutics ( (VIRX) ) just unveiled an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Viracta Therapeutics has announced the closure of its NAVAL-1 clinical trial for Nana-val in relapsed/refractory EBV+ lymphomas to conserve resources while exploring strategic alternatives, including potential mergers or sales. The company reassured stakeholders that the trial’s closure was not due to safety concerns and emphasized its commitment to maximizing shareholder value through various strategic options.
More about Viracta Therapeutics
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers affecting patients globally. Its lead product candidate is Nana-val, an all-oral combination therapy currently under evaluation in various clinical trials for treating relapsed or refractory Epstein-Barr virus-positive lymphomas and other virus-related cancers.
YTD Price Performance: -56.14%
Average Trading Volume: 2,237,923
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.94M
For an in-depth examination of VIRX stock, go to TipRanks’ Stock Analysis page.
